We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+12.82%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$13.3B
AUM Growth
+$1.51B
Cap. Flow
+$1.01B
Cap. Flow %
7.58%
Top 10 Hldgs %
83.56%
Holding
124
New
10
Increased
16
Reduced
22
Closed
5

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$1.09B
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$97.2M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$84.2M
4
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$54.3M
5
TCDA
Tricida, Inc. Common Stock
TCDA
+$44.7M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$144M
2
ABLX
Ablynx NV
ABLX
+$119M
3
NKTR icon
Nektar Therapeutics
NKTR
+$29.3M
4
EXEL icon
Exelixis
EXEL
+$13.4M
5
PGNX
Progenics Pharmaceuticals Inc
PGNX
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 92.38%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TCDA
26
DELISTED
Tricida, Inc. Common Stock
TCDA
$47.8M 0.36%
+1,600,000
New +$44.7M
GWPH
27
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$44.9M 0.34%
321,800
+100,000
+45% +$14.2M
ABEO icon
28
Abeona Therapeutics
ABEO
$342M
$35M 0.26%
87,375
– –
PHXM
29
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$34.5M 0.26%
308,597
-410
-0.1% -$77K
XNCR icon
30
Xencor
XNCR
$1.45B
$32.3M 0.24%
872,072
– –
ECYT
31
DELISTED
Endocyte, Inc. Common Stock
ECYT
$31.4M 0.24%
2,277,799
– –
BLUE
32
DELISTED
bluebird bio
BLUE
$31.4M 0.24%
15,440
– –
BLCM
33
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$30.2M 0.23%
409,345
-5,813
-1% -$453K
NGNE icon
34
Neurogene
NGNE
$648M
$29M 0.22%
546,708
– –
MRUS
35
DELISTED
Merus
MRUS
$26.4M 0.2%
1,160,014
– –
LKFT
36
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$24M 0.18%
259,894
– –
QURE icon
37
uniQure
QURE
$2.76B
$22.9M 0.17%
605,000
+105,000
+21% +$3.36M
HALO icon
38
Halozyme
HALO
$9.82B
$21.7M 0.16%
1,283,929
-297,495
-19% -$5.62M
MYOK
39
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$21.5M 0.16%
433,121
+142,857
+49% +$6.92M
SLDB icon
40
Solid Biosciences
SLDB
$791M
$20.9M 0.16%
39,192
– –
ZYME icon
41
Zymeworks
ZYME
$1.61B
$19.4M 0.15%
+1,311,085
New +$20.3M
SGMO
42
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$18.2M 0.14%
1,283,923
-323,656
-20% -$5.38M
AIMT
43
DELISTED
Aimmune Therapeutics
AIMT
$18.1M 0.14%
673,908
– –
INSM icon
44
Insmed
INSM
$22.5B
$16.6M 0.12%
700,000
– –
CFRX
45
DELISTED
ContraFect Corporation
CFRX
$15.8M 0.12%
8,941
– –
CMTA
46
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$15.7M 0.12%
1,192,595
+942,595
+377% +$15.3M
BOLD
47
DELISTED
Audentes Therapeutics, Inc
BOLD
$15M 0.11%
393,222
– –
NTLA icon
48
Intellia Therapeutics
NTLA
$1.5B
$15M 0.11%
546,922
-286,873
-34% -$6.95M
SYRE icon
49
Spyre Therapeutics
SYRE
$8.26B
$14.7M 0.11%
55,515
+10,000
+22% +$2.46M
CPRX
50
DELISTED
Catalyst Pharmaceutical
CPRX
$11.3M 0.08%
3,621,962
-759,110
-17% -$2.3M
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2018 Portfolio in Review

As of Q2 2018, Baker Bros. Advisors held 124 positions worth $13.3B, up 13% from $11.8B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Baker Bros. Advisors deployed $1.01B of net new capital in Q2 2018, opening 10 new positions and adding to 16 existing holdings. Its largest new stake was Kiniksa Pharmaceuticals: 3,000,000 shares worth $52M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 94% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Exelixis, an estimated $13.4M trimmed.

  • Baker Bros. Advisors's largest Q2 2018 buy was Kiniksa Pharmaceuticals: 3,000,000 shares worth $52M.
  • Baker Bros. Advisors added most to BeOne Medicines Ltd in Q2 2018, an estimated $1.09B increase.
  • Baker Bros. Advisors's biggest Q2 2018 reduction was Exelixis, cutting an estimated $13.4M.
  • Baker Bros. Advisors fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $144M.
  • Baker Bros. Advisors's ten largest holdings make up 84% of its $13.3B portfolio in Q2 2018.
  • Baker Bros. Advisors opened 10 new positions and closed 5 in Q2 2018.
  • Baker Bros. Advisors's portfolio value rose 13% quarter-over-quarter to $13.3B.

Based on Baker Bros. Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.